多发性骨髓瘤治疗与疗效评估的新进展
本文综述多发性骨髓瘤治疗领域的创新策略,重点讨论免疫治疗与高剂量治疗带来的高缓解率与延长缓解期,以及18F-FDG PET/CT在诊断分期与疗效评估中的核心作用,并介绍PET代谢完全缓解标准的标准化、放射组学与新型放射性药物的发展前景。
要点
- 18F-FDG PET/CT可用于多发性骨髓瘤诊断分期与疗效评估,兼顾髓内与髓外病变评估。
- 基线PET参数(髓外/旁髓病变、局灶性骨病灶数目、SUVmax)具独立阴性预后价值。
- 疗效评估中18F-FDG PET/CT被视为参考影像技术,可较缺乏特异性的MRI更早进行。
核心结论
- 免疫治疗与高剂量治疗等创新策略显著改善了多发性骨髓瘤的治疗格局,缓解率高且缓解持续时间延长。
- 18F-FDG PET/CT是多发性骨髓瘤诊断分期与疗效评估的有力影像工具,并可提供独立的阴性预后信息。
- PET代谢完全缓解的定义已标准化、判读标准已协调统一,先进PET分析、放射组学及新型放射性药物为骨髓瘤影像带来新前景。
研究设计与样本
- 本文为综述,围绕多发性骨髓瘤治疗新进展与疗效评估影像方法进行论述。
主要发现
- 免疫治疗与高剂量治疗的开发与应用显示出高缓解率并延长了缓解持续时间。
- 近十年来新的形态学或混合影像技术逐渐取代传统骨骼检查。
- 多项大型前瞻性研究报道,基线PET参数如髓外病变或旁髓病变的存在、局灶性骨病灶数目及SUVmax对无进展生存和总生存具有独立阴性预后价值。
- 治疗后持续存在显著异常18F-FDG摄取是独立阴性预后因素,18F-FDG PET/CT与髓内流式细胞术在维持治疗前检测微小残留病方面互为补充。
- C-X-C趋化因子受体4靶向小分子与抗CD38放射性标记抗体等新型放射性药物在肿瘤表型显像及潜在诊疗一体化方面显示出有前景的结果。
关键数值与推荐
- 疗效评估中18F-FDG PET/CT被认为是参考影像技术,因其可较缺乏特异性的MRI更早进行。
- PET代谢完全缓解的定义最近已标准化,判读标准已协调统一。
临床怎么用
- 18F-FDG PET/CT可用于多发性骨髓瘤诊断时的检查评估及治疗评估,实现髓内和髓外病变评估。
- 治疗评估中可将18F-FDG PET/CT作为参考影像技术,并与髓内流式细胞术互补用于维持治疗前微小残留病检测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent innovative strategies have dramatically redefined the therapeutic landscape for treating multiple myeloma patients. In particular, the development and application of immunotherapy and high-dose therapy have demonstrated high response rates and have prolonged remission duration. Over the past decade, new morphologic or hybrid imaging techniques have gradually replaced conventional skeletal surveys. PET/CT using 18F-FDG is a powerful imaging tool for the workup at diagnosis and for therapeutic evaluation allowing medullary and extramedullary assessment. The independent negative prognostic value for progression-free and overall survival derived from baseline PET-derived parameters such as the presence of extramedullary disease or paramedullary disease, as well as the number of focal bone lesions and SUVmax, has been reported in several large prospective studies. During therapeutic evaluation, 18F-FDG PET/CT is considered the reference imaging technique because it can be performed much earlier than MRI, which lacks specificity. Persistence of significant abnormal 18F-FDG uptake after therapy is an independent negative prognostic factor, and 18F-FDG PET/CT and medullary flow cytometry are complementary tools for detecting minimal residual disease before maintenance therapy. The definition of a PET metabolic complete response has recently been standardized and the interpretation criteria harmonized. The development of advanced PET analysis and radiomics using machine learning, as well as hybrid imaging with PET/MRI, offers new perspectives for multiple myeloma imaging. Most recently, innovative radiopharmaceuticals such as C-X-C chemokine receptor type 4-targeted small molecules and anti-CD38 radiolabeled antibodies have shown promising results for tumor phenotype imaging and as potential theranostics.
引用
- Kraeber-Bodéré F, Jamet B, Bezzi D, et al. New Developments in Myeloma Treatment and Response Assessment. J Nucl Med. 2023. PMID: 37591548. doi:10.2967/jnumed.122.264972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。